tion in patients with chronic myeloid leukemia LY317615 Enzastaurin resistant to imatinib. Leuk Res. 2010, 34:143�?. 16. Oyekunle A, Klyuchnikov E, Ocheni S, et al. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol. 2011, 126:30�?. 17. Venepalli N, Rezvani K, Mielke S, Savani BN. Role of allo-SCT for CML in 2010. Bone Marrow Transplant. 2010, 45:1579�?6. 18. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986, 314:1065�?. 19. Dowding C, Gordon M, Guo AP, et al. Potential mechanisms of action of interferon-alpha in CML. Leuk Lymphoma.
1993, 11 :185�?1. 20. Guilhot F, Lacotte-Thierry L. Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase. Hematol Cell Ther. 1998, 40:237�?. 21. Ohnishi K, Ohno R, Tomonaga M, et al. Factor Xa activity A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995, 86:906�?6. Woessner et al. Page 10 Cancer J. Author manuscript, available in PMC 2012 May 1. NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript 22. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med. 1994, 330:820�?. 23. Beck JR, Guilhot J, Giles FJ, Aoki N, Wirt DP, Guilhot F.
Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia. Leuk Lymphoma. 2001, 41:117�?4. 24. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999, 94:1517�?6. 25. Silberman G, Crosse MG, Peterson EA, et al. Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med. 1994, 331:1063�?. 26. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia.
N Engl J Med. 2010, 362:2260�?0. 27. Nicolini FE, Turkina A, Shen ZX, et al. Expanding Nilotinib Access in Clinical Trials : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer. 2011 28. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010, 362:2251�?. 29. Deininger M, O,Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib. ASH Annual Meeting Abstracts.
2009, 114:1126. 30. Corm S, Micol J, Leroyer A, et al. Kinetic of chronic myeloid leukaemia prevalence in Northern France since the introduction of imatinib. J Clin Oncol. May 20.2008 26 abstr 7088. 31. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008, 49:615�?. 32. Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Soverini S. Response definitions and European Leukemianet Management recommendations. Best Pract Res Clin Haematol. 2009, 22:331�?1. 33. Hughes TP, Kaeda J, Branford